Supplementary Materials

Supplementary Materials for:

MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)–addicted neuroblastomas

Ganesh Umapathy, Jikui Guan, Dan E. Gustafsson, Niloufar Javanmardi, Diana Cervantes-Madrid, Anna Djos, Tommy Martinsson, Ruth H. Palmer, Bengt Hallberg*

*Corresponding author. Email: bengt.hallberg{at}gu.se

This PDF file includes:

  • Fig. S1. SNP array genome profiles of the nine neuroblastoma cell lines.
  • Fig. S2. NF1 abundance in neuroblastoma cell lines.
  • Fig. S3. Sensitivity of neuroblastoma cell lines to trametinib.
  • Fig. S4. AKT signaling inhibition does not lead to increased activation of MAPK.
  • Fig. S5. Sensitivity of EML4-ALK–positive NSCLC cell lines to trametinib.
  • Fig. S6. Phospho-RTK array analysis after MEK inhibition.
  • Fig. S7. Increased AKT activation in cells upon treatment with trametinib and rapamycin.
  • Fig. S8. Increased AKT activation in xenografts upon treatment with trametinib.
  • Table S1. Chromosomal profiles of the cell lines.
  • Table S2. Trametinib does not act synergistically with lorlatinib to inhibit ALK-positive neuroblastoma cell line proliferation.
  • Reference (76)

[Download PDF]

Technical Details

Format: Adobe Acrobat PDF

Size: 1.68 MB


Citation: G. Umapathy, J. Guan, D. E. Gustafsson, N. Javanmardi, D. Cervantes-Madrid, A. Djos, T. Martinsson, R. H. Palmer, B. Hallberg, MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)–addicted neuroblastomas. Sci. Signal. 10, eaam7550 (2017).

© 2017 American Association for the Advancement of Science